Dual‑source CMC. Switch vendors in 60–90 days.

China Strategy: Building Optionality Without Abandoning Speed

China remains unmatched for clinical trial enrollment and manufacturing capacity. But over the past year, "business as usual" has become a board-level question.

It's not whether to work with China—it's how to preserve optionality while you do.

The Pattern: Exposure That Surfaces Late

Most biotech teams know they have China dependencies. What catches them off guard:

• A partnership term sheet that requires supply chain diversification within 6 months

• An acquirer flagging China-only clinical data as a diligence issue

• A board asking "if BIOSECURE expands, what's our switching timeline?" and realizing the answer is "12+ months"

Is this on your radar?

Ask your team: "If we lost access to our primary Chinese CDMO tomorrow, how long to switch to an alternate?"

If the answer is "6+ months" or "we'd have to re-qualify from scratch," you have critical-path exposure without contingency.

What Prepared Companies Are Doing

The teams moving proactively aren't abandoning China relationships. They're building structured optionality—the ability to pivot if policy or partnership requirements change.

Three areas getting focused attention:

1. Map exposure by critical path, not just vendor list

Most companies have a spreadsheet of Chinese vendors. The prepared ones have mapped which dependencies actually gate their IND or BLA filing.

What this means:

• Tox studies: Can you refile with ex-China data if a partner requires it?

• Drug substance/drug product (DS/DP): Is your tech transfer package documented well enough to move to an alternate site?

• Analytics and assays: Are your biomarker assays validated at labs outside China?

The distinction: Critical path (can't file without it) vs. convenient (replaceable if needed).

What this looks like in practice:

One mid-stage oncology company mapped their exposure and realized:

• Primary CDMO (China) - critical path for DS/DP

• Backup CDMO (also China) - not true redundancy

• Tox lab (China) - critical path for IND filing

• Three CROs (China) - 70% of Phase 2 enrollment

If policy changed or a partner required diversification, they had three critical-path items all in one jurisdiction with no validated alternates. Switching timeline: 9-12 months.

What they did:

Identified the two items that truly blocked their filing (DS/DP manufacturing, tox studies) and prioritized those for contingency planning. The CRO relationships were important but not blocking—they could adjust enrollment mix more easily.

What boards are asking: "If policy changes or a partner flags this, what's our switching timeline and cost?"

Having this mapped before they ask changes the conversation from "we'll look into it" to "here's our exposure and contingency plan."

2. Qualify alternates now, even if you don't switch

The companies with real optionality aren't waiting to be forced. They're qualifying alternate ex-China vendors proactively—even while continuing with their primary Chinese partner.

The "warm standby" approach:

• Identify 1-2 alternate vendors (US, EU, South Korea, India depending on your needs)

• Run 1-2 small validation lots to prove your tech transfer package actually works

• Document the process so switching isn't starting from zero

Why this matters:

If you wait until you're forced to switch (policy change, partnership requirement), you're looking at 6-12 months to qualify a new vendor. If you've already done the groundwork, that timeline drops to 6-12 weeks.

What this looks like:

That same oncology company:

• Ran 2 validation lots with a South Korean CDMO (4 months, ~$200K)

• Ran 1 validation lot with a US tox lab (3 months, ~$150K)

• Documented comparability so switching wouldn't require full re-qualification

Total investment: ~$350K and 4 months of effort. But now their switching timeline went from 9-12 months (cold start) to 6-8 weeks (warm standby).

The board conversation changed: Instead of "we're dependent on China," it became "we're using China for speed, and we have documented alternates if policy or partnerships require it."

The target most companies are using: Reduce single-jurisdiction critical-path exposure to under 30%. That doesn't mean moving everything out of China—it means ensuring no single jurisdiction can stop your program.

The tradeoff: This costs money upfront (validation lots, vendor qualification). The ROI is insurance—and increasingly, it's what partners and acquirers expect to see in diligence.

3. Make tech transfer actually transferable

The most common reason switching takes 9-12 months instead of 6-8 weeks: the tech transfer package isn't actually complete.

What "incomplete" looks like:

• SOPs exist but critical parameters are in people's heads ("we usually run it at X, but if Y happens we adjust to Z")

• Validation methods are documented but acceptance criteria have shifted over time

• Deviation history exists but root cause analysis and resolution approaches aren't captured

When you try to transfer to a new vendor, they can't recreate your process from the documentation alone.

What's working:

Companies are treating tech transfer packages like they treat regulatory submissions—complete, standalone, validated.

What a complete package includes:

• Master batch records with parameter windows (not just target values, but acceptable ranges)

• Analytical methods with validation protocols and acceptance criteria

• Deviation history with root causes and resolution approaches

• Critical quality attributes (CQAs) and their acceptable ranges

The test: Could a competent vendor recreate your process from this package with minimal back-and-forth?

If not, it's not complete enough for a fast switch.

4. Build optionality into contracts from the start

Most legacy contracts with Chinese vendors were signed when speed was the priority. They often lack:

• Step-in rights (what happens if the vendor can't perform?)

• Change-of-law clauses (what happens if policy changes?)

• Data residency requirements (where can your data be stored/accessed?)

• Audit rights (can you verify their processes?)

What's working:

For new contracts or renewals, companies are adding:

Step-in rights: If vendor can't meet timelines or quality standards, you have the right to bring in an alternate vendor or take work in-house with vendor's cooperation.

Change-of-law clauses: If regulatory or policy changes affect the vendor's ability to perform, both parties have defined obligations and timelines for transitioning work.

Data residency: Explicit requirements about where data can be stored, who can access it, and under what conditions.

Audit rights: Regular scheduled audits plus for-cause audits if quality or compliance concerns arise.

When this matters: For critical-path vendors (DS/DP, tox, key analytics). For non-critical vendors, standard terms are usually fine.

What Good Looks Like

You'll know optionality is real when:

• Someone asks "Who's in charge of the IND?" and everyone gives the same name

• Board asks about China exposure and you can show a map with contingency timelines

• Partnership discussions don't stall on supply chain questions

• You have pricing leverage at vendor renewals (because switching is credible)

Most reliable early signal: When your board asks about China risk and you can walk them through your exposure map, validated alternates, and switching timeline—without scrambling to create that analysis on the spot.

When This Actually Matters

China contingency planning is urgent if:

• Phase 2+ companies (partnerships/exits are realistic near-term)

• Critical manufacturing or tox in single jurisdictions

• Board/investor pressure on China risk

Probably too early if:

• Pre-IND with minimal China dependencies

• Discovery-stage (no manufacturing or clinical exposure yet)

• China relationships are for non-critical-path work

Honest answer: Early-stage companies often lean heavily on China for speed and cost, and that's fine. But heading toward IND or partnership discussions, having a contingency plan matters—not because you'll necessarily execute it, but because partners and investors will ask about it.

How to Start

Step 1: Map your critical path (2-4 weeks)

List every China dependency. For each, ask:

• Does this gate our IND/BLA filing?

• If we lost access, what's the switching timeline?

• Do we have documentation that would enable a transfer?

Focus on the 2-3 items that are truly blocking.

Step 2: Qualify one alternate for your highest-risk item (3-6 months)

Pick your most critical China dependency (usually DS/DP manufacturing or tox). Identify 1-2 alternates and run small validation lots to prove your tech transfer works.

Step 3: Document as you go (ongoing)

For any new China relationships, build optionality into contracts:

• Step-in rights

• Change-of-law clauses

• Data residency requirements

• Audit rights

For existing critical-path vendors, renegotiate these terms at renewal.

What Are You Seeing?

Are you facing board or investor questions about China exposure? And what's the actual constraint—technical (switching is hard), financial (alternates cost more), or strategic (you want China relationships but need documented optionality)?

Worth comparing notes.

—Roop